SEND SMS
SEND EMAIL

Anticancer

Pioneers in the industry, we offer anastrozole tablets 1mg, cisplatin injection 10mg/50mg, cytarabine injection bp 100mg/ 500mg/ 1000mg, gefitinib tablets 250mg, irinotecan injection 100mg/40mg and l-asparaginase for injection 5000i.u/ 10000i.u from India.

Anastrozole Tablets 1mg

Anastrozole Tablets 1mg
  • Anastrozole Tablets 1mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose1mg
Packaging TypeBox
Packaging Size1 Strip of 10 tabs
BrandANTRAX-FH
UsageClinical, Hospital, Personal
CompositionAnastrozole Tablets

Indications:
  • Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women
  • Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women.
  • Adjuvant treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Dosage:
  • The recommended dose of Anastrozole for adults including the elderly is one 1mg tablet once a day.
Request
Callback
Yes! I am Interested

Cisplatin Injection 10mg/50mg

Cisplatin Injection 10mg/50mg
  • Cisplatin Injection 10mg/50mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose10mg/50mg
Packaging TypeBox
BrandCISFLO
Packaging Size1 vial of 10mg/10ml and 50mg/50ml
UsageClinical, Hospital, Personal
CompositionCisplatin Injection

Indications:
  • To be used as mono-therapy, or as part of an existing chemotherapy for advanced or metastatic tumours: testicular carcinoma (palliative and curative poly-chemotherapy) and ovary carcinoma (stages III and IV), and head and neck squamous-cell epithelioma (palliative therapy).
  • In the treatment of small cell lung carcinoma.
  • In the treatment of advanced non-small cell lung carcinoma.

Dosage:
  • Single dose of 50 to 120 mg/m2 body surface every 3 to 4 weeks.
  • 15 to 20 mg/m2/day for five days, every 3 to 4 weeks.
  • If cisplatin is used in combination chemotherapy, the dose of cisplatin must be reduced.
  • A typical dose is 20 mg/m2 or more once every 3 to 4 weeks unless in the combination therapy of small-cell and non-small-cell lung carcinoma, in which a typical dose of 80 mg/m2 is administered.
Request
Callback
Yes! I am Interested

Cytarabine Injection BP 100mg/ 500mg/ 1000mg

Cytarabine Injection BP 100mg/ 500mg/ 1000mg
  • Cytarabine Injection BP 100mg/ 500mg/ 1000mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose100mg/500mg/1000mg
Packaging TypeBox
BrandCYTRABIN
Packaging Size1 vial of 100mg/500mg/1000mg
UsageClinical, Hospital, Personal
CompositionCytarabine Injection BP

Indications:
  • Cytarabine may be used alone or in combination with other antineoplastic agents.
  • It is indicated alone or in combination for induction of remission and/or maintenance in patients with acute myeloid leukemia, acute non-lymphoblastic leukaemias, acute lymphoblastic leukaemias, acute lymphocytic leukaemia, erythroleukaemia, blast crises of chronic myeloid leukaemia, diffuse histiocytic lymphomas (non-Hodgkin's lymphomas of high malignancy), meningeal leukaemia and meningeal neoplasms.
  • Clinicians should refer to the current literature on combination therapy before initiating treatment.

Dosage:
  • Remission Induction: Adults
  • Continuous Dosing: The usual dose in leukaemia is 2 mg/kg by rapid intravenous injection daily for ten days. If after ten days neither therapeutic response nor toxicity has been observed, the dose may be increased to 4 mg/kg until a therapeutic response or toxicity is evident.
  • Intermittent dosing: 3-5 mg/kg daily, for five consecutive days. This course of treatment can be repeated after an interval of 2 to 9 days.
Request
Callback
Yes! I am Interested

Gefitinib Tablets 250mg

Gefitinib Tablets 250mg
  • Gefitinib Tablets 250mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging TypeBox
Packaging Size1x10 tablets
BrandGEFLO
Dose/Strength250 mg
UsageHospital Personal
CompositionGefitinib Tablets

Indication:
  • Is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.

Dosage:
  • Adult: 250 mg tablet once a day, taken with or without food.

Request
Callback
Yes! I am Interested

Irinotecan Injection 100mg/40mg

Irinotecan Injection 100mg/40mg
  • Irinotecan Injection 100mg/40mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose100mg/40mg
Packaging TypeBox
BrandIRINOCAN
Packaging Size1 vial of 2ml/5 ml
UsageClinical, Hospital, Personal
CompositionIrinotecan Injection

Indications:
  • Carcinoma of the Colon or Rectum.
  • Metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

Dosage:
  • Colorectal cancer single agent regimen 1: Irinotecan Hydrochloride Injection, 125 mg/m2 intravenous infusion over 90 minutes on days 1, 8, 15, 22 then 2-week rest. (2.1)
  • Colorectal cancer single agent regimen 2: Irinotecan Hydrochloride Injection, 350 mg/m2 intravenous infusion over 90 minutes on day 1 every 3 weeks. (2.1)
Request
Callback
Yes! I am Interested

L-Asparaginase For Injection 5000I.U/ 10000I.U

L-Asparaginase For Injection 5000I.U/ 10000I.U
  • L-Asparaginase For Injection 5000I.U/ 10000I.U
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose5000i.u/10000i.u
Packaging TypeBox
BrandLASGIN
Packaging Size1 vial
UsageClinical, Hospital, Personal
CompositionL-Asparaginase for Injection

Indications:
  • Is used in combination with other anti-neoplastic agents to treat acute lymphoblastic leukaemia.
  • It may also be used in other neoplastic conditions where depletion of asparagine might be expected to have a useful effect.
  • Patients receiving treatment with L-asparaginase from Escherichia coli, and who develop hypersensitivity to that enzyme may be able to continue treatment with as the enzymes are immunologically distinct.

Dosage:
  • The usual dosage range for L-Asparaginase is 50 to 200 KU/kg bodyweight daily or every alternate day, given intravenously or intramuscularly.
  • Test Dose: Before treatment is started a test dose of 1 to 10 KU of L-Asparaginase in 0.1 ml of distilled water should be injected subcutaneously and the injection site observed for several hours of evidence of primary hypersensitivity.
Request
Callback
Yes! I am Interested

Lenalidomide Capsules

Lenalidomide Capsules
  • Lenalidomide Capsules
Ask For Price
Product Price :Get Latest Price

Product Details:

BrandLENDOMIDE
Packaging TypeBox
Strength (mg)5mg/10mg
UsageClinic
Packaging Size1x10 capsules
CompositionLenalidomide Capsules

Indications:
  • Multiple myeloma: As monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.
  • As combination therapy is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
  • Myelodysplastic syndromes (MDS):- As monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

Dosage:
  • MDS: PO 10mg OD
  • Multiple Myeloma: PO 25mg once daily on days 1 to 21 of repeated 28 day cycles.
  • Note – Dosage adjustment is required in case of thrombocytopenia and neutropenia.
Request
Callback
Yes! I am Interested

Methotrexate Injection USP 50mg/ 100mg

Methotrexate Injection USP 50mg/ 100mg
  • Methotrexate Injection USP 50mg/ 100mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose50mg/100mg
Packaging TypeBox
BrandMETHOXTE
Packaging Size1 vial of 2ml/4ml
UsageClinical, Hospital, Personal
CompositionMethotrexate Injection USP

Indications:
  • Trophoblastic neoplasms (chorioadenoma destruens, choriocarcinoma, and hydatidiform mole).
  • Acute lymphocytic leukemia (ALL)
  • Meningeal leukemia or meningeal leukemia
  • Breast cancer
  • Head and neck cancer
  • Cutaneous T-cell lymphoma (mycosis fungoides)
  • Lung cancer
  • Non-Hodgkin's lymphoma (NHL)
  • Burkitt's Lymphoma
  • Osteogenic sarcoma

Dosage:
  • Trophoblastic Neoplasms Adults: 15-30mg peroral (PO)/ intramuscular (IM) once daily, given for 5 days.
  • Acute Lymphocyic Leukemia Adults & children: 3.3mg/m2 IV daily for 4-6 weeks or followed by maintenance therapy with 20-30mg/m2/PO/IM given twice weekly.
  • Breast Cancer Adults & Children: 40-60mg/m2 IV given on day 1 of every 21-28 days along with cyclophosphamide & fluorouracil.
  • Head & Neck Cancer Adults & Children: 40mg/m2 IV on days 1 & 15 of every 21 days alone or with bleomycin & cisplatin.
  • Cutaneous T-cell Lymphoma Adults: 50mg IM once weekly or 25mg twice weekly.
  • Lung Cancer: Methotrexate 20mg/m2 IV as a single dose along with cisplatin, doxorubicin & cyclophosphamide repeated every 28 days.
Request
Callback
Yes! I am Interested

Thalidomide Capsules 50mg/ 100mg/ 200mg

Thalidomide Capsules 50mg/ 100mg/ 200mg
  • Thalidomide Capsules 50mg/ 100mg/ 200mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging TypeBox
Packaging Size1x10 capsules
BrandTHAMIDE
UsageClinic,Hospital,Personal
Dose50mg/100mg/200mg
CompositionThalidomide Capsules

Indications:
  • Thalidomide in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.
  • Thalidomide is prescribed and dispensed according to the Thalidomide Pregnancy Prevention Programme.

Dosage:

Multiple Myeloma:
  • Thalidomide is administered in combination with dexamethasone in 28-day treatment cycles. The dose of thalidomide is 200 mg administered orally once daily with water, preferably at bedtime and at least 1 hour after the evening meal. The dose of dexamethasone is 40 mg daily administered orally on days 1-4, 9-12, and 17-20 every 28 days. Patients who develop adverse reactions such as constipation, somnolence, or peripheralneuropathy may benefit by either temporarily discontinuing the drug or continuing at a lower dose. With the abatement of these adverse reactions, the drug may be started at a lower dose or at the previous dose based on clinical judgment.

Cardiac Transplantation:
  • 1.5 g intravenously twice a day administered over no less than 2 hours or 1.5 g orally twice a day.
Request
Callback
Yes! I am Interested

Topotecan Injection 2.5mg/4mg

Topotecan Injection 2.5mg/4mg
  • Topotecan Injection 2.5mg/4mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose2.5mg/4mg
Packaging TypeBox
BrandTOPOCAN
Packaging Size1 vial of 2.5ml/4ml
UsageClinical, Hospital, Personal
CompositionTopotecan Injection

Indications:
  • Metastatic carcinoma of the ovary after failure of initial or subsequent chemo therapy. 
  • Small cell lung cancer disease after failure of first line chemotherapy.

Dosage:
  • The recommended starting dose is 1.5mg/m2 body surface area by IV infusion over 30 minutes daily for 5 consecutive days.
  • In absence of tumor progression, a minimum of four courses are recommended, as tumour response may be delayed.
Request
Callback
Yes! I am Interested

Vinblastine Sulphate Injection 10mg

Vinblastine Sulphate Injection 10mg
  • Vinblastine Sulphate Injection 10mg
Ask For Price
Product Price :Get Latest Price

Product Details:

UsageClinical, Hospital, Personal
Packaging Size1 vial of 10 ml
Packaging TypeBox
BrandVINBLAST
Dose/Strength10 mg
CompositionVinblastine Sulphate Injection

Indications:
  • Frequently Responsive Malignancies
  • Generalized Hodgkin's disease (Stages III & IV).
  • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated).
  • Histiocytic lymphoma.
  • Mycosis fungoides (advanced stages).
  • Advanced carcinoma of the testis (embryonal carcinoma, teratocarcinoma & choriocarcinoma).
  • Kaposi's sarcoma.
  • Less Frequently Responsive Malignancies
  • Choriocarcinoma resistant to other chemotherapeutic agents.
  • Carcinoma of the breast, unresponsive to appropriate endocrine surgery & hormonal therapy.

Dosage:
  • Adults: A single IV dose of 3.7 mg/m2 of body surface area for 4-6 weeks.
  • Children: 6 mg/m2 of body surface area with other chemotherapeutic agents.
Request
Callback
Yes! I am Interested

Vincristine Sulfate Injection USP 1mg/ 2mg

Vincristine Sulfate Injection USP 1mg/ 2mg
  • Vincristine Sulfate Injection USP 1mg/ 2mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose1mg/2mg
Packaging TypeBox
BrandVINTINE
Packaging Size1 vial 1ml/2ml
UsageClinical, Hospital, Personal
CompositionVincristine Sulfate Injection USP

Indications:
  • Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia
  • Malignant lymphomas, including Hodgkin's disease and non-Hodgkin's lymphomas.
  • Solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas.
  • Paediatric solid tumours, including Ewing's sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms' tumour, retinoblastoma and medulloblastoma

Dosage:
  • Adults: 1.4 mg/m2 IV once weekly (typical dose 2 mg)
  • Children: 1.4 to 2 mg/m2 given on a weekly basis with a maximum weekly dose of 2 mg.        
  • Elderly: l Body weight more than 10 kg or body surface area of 1 m2 or more - 1 to 2 mg/m2 IV once weekly.
  • l Body weight less than or equal to 10 kg or Body surface area less than 1 m2 or more - 0.05 mg/kg IV once weekly initially. Titrate dose as tolerated up to 2 mg/dose.
  • Hepatic Impairment: A 50 per cent reduction in the dose of vincristine sulphate is recommended for patients having a direct serum bilirubin value above 3 mg/100 ml (51 micromol/l).
Request
Callback
Yes! I am Interested

Vinorelbine Injection 10mg /20mg/ 50mg

Vinorelbine Injection 10mg /20mg/ 50mg
  • Vinorelbine Injection 10mg /20mg/ 50mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose10mg, 20mg,50mg
Packaging Size1 vial 1ml/2ml/5ml
Packaging TypeBox
BrandFLOVINREL
UsageClinical, Hospital, Personal
CompositionVinorelbine Injection

Indications:
  • Non small cell lung carcinoma, breast carcinoma, Hodgkin's disease, ovarian carcinoma, squamous cell carcinoma of the head and neck, cervical, SCLC, renal cell cancer and kaposi's sarcoma.

Dosage:
  • Initial dose of 30mg/m² weekly over a period of 6-10 min.
  • No dose adjustment is required for renal insufficiancy
Request
Callback
Yes! I am Interested

Bleomycin Injection 15 Units

Bleomycin Injection 15 Units
  • Bleomycin Injection 15 Units
Ask For Price
Product Price :Get Latest Price

Product Details:

DoseSingle dose vial
Packaging Size1 vial of 15 units
Packaging TypeBox
BrandBLOCIN-F
CompositionBleomycin Injection

Indication:
  • Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesophagus, external, cervix or skin. Well differentiated tumours usually respond better than anaplastic ones.
  • Hodgkin's disease and other malignant lymphomas, including mycosis fungoides.
  • Testicular teratoma
  • Malignant effusions of serous cavities.
  • Secondary indications in which bleomycin has been shown to be of some value (alone or in combination with other drugs) include metastatic malignant melanoma, carcinoma of the thyroid, lung and bladder.

Dosage:
  • Used alone the normal dosage is 15 x 103 IU (1 vial) three times a week or 30 x 103 IU (2 vials) twice a week, either intramuscularly or intravenously.
Request
Callback
Yes! I am Interested

Bortezomib For Injection 2mg 3.5mg

Bortezomib For Injection 2mg 3.5mg
  • Bortezomib For Injection 2mg 3.5mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size1 vial of 2mg, 3.5mg
Packaging TypeLyophilized Injection
Dose/Strength2mg/3.5mg
UsageClinical, Hospital, Personal
BrandFLOBORT

Indications:
  • Bortezomib is used for the treatment of people with multiple myeloma (a cancer of the plasma cells) and mantle cell lymphoma (a cancer of the lymph nodes).

Dosage:

Monotherapy:
  • 3.5 mg powder for solution for injection is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21-day treatment cycle.
  • This 3-week period is considered a treatment cycle. It is recommended that patients receive 2 cycles following a confirmation of a complete response.
  • It is also recommended that responding patients who do not achieve a complete remission receive a total of 8 cycles.
  • At least 72 hours should elapse between consecutive doses.

Dose adjustments during treatment and re-initiation of treatment for monotherapy:
  • Treatment must be withheld at the onset of any Grade 3 non-haematological or any Grade 4 haematological toxicities, excluding neuropathy as discussed below.
  • Once the symptoms of the toxicity have resolved, treatment may be re-initiated at a 25% reduced dose (1.3 mg/m2 reduced to 1.0 mg/m2; 1.0 mg/m2 reduced to 0.7 mg/m2).
  • If the toxicity is not resolved or if it recurs at the lowest dose, discontinuation of must be considered unless the benefit of treatment clearly outweighs the risk.
Request
Callback
Yes! I am Interested

Carboplatin Injection BP

Carboplatin Injection BP
  • Carboplatin Injection BP
Ask For Price
Product Price :Get Latest Price

Product Details:

UsagePersonal, Clinical, Hospital
Dose150mg/450mg/600mg
Packaging Size1 Vial of 150 mg /15 ml, 450 mg/45 ml & 600 mg/60 ml
Packaging TypeLiquid Injection
BrandCARBO-FH-150

Indications:
  • Advanced ovarian carcinoma of epithelial origin in:
  • First line therapy
  • Second line therapy, after other treatments have failed.
  • Small cell carcinoma of the lung.

Dosage:
  • Carboplatin should be used by the intravenous route only.
  • The recommended dosage of Carboplatin in previously untreated adult patients with normal kidney function, i.e. creatinine clearance > 60 ml/min is 400 mg/m2 as a single short term IV dose administered by a 15 to 60 minutes infusion
Request
Callback
Yes! I am Interested

Dacarbazine for Injection USP 100mg/ 200mg/ 500mg/ 1000mg

Dacarbazine for Injection USP 100mg/ 200mg/ 500mg/ 1000mg
  • Dacarbazine for Injection USP 100mg/ 200mg/ 500mg/ 1000mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose/Strength100mg, 200mg, 500mg & 1000mg
Packaging Size1 vial 100ml, 200ml, 500ml, 1000ml
Packaging TypeBox
BrandFLODAC
CompositionDacarbazine for Injection USP

Indications:
  • Dacarbazine is indicated for the treatment of patients with metastasised malignant melanoma.

Further indications for dacarbazine as part of a combination chemotherapy are:
  • Advanced Hodgkin's disease,
  • Advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma).

Dosage:

Malignant melanoma:
  • Dacarbazine can be administered as single agent in doses of 200 to 250 mg/m2 body surface area/day as an i.v. injection for 5 days every 3 weeks.
  • As an alternative to an intravenous bolus injection dacarbazine can be administered as a short-term infusion (over 15 - 30 minutes).
  • It is also possible to give 850 mg/m2 body surface area on day 1 and then once every 3 weeks as intravenous infusion.
Request
Callback
Yes! I am Interested

Dactinomycin For Injection USP 500mcg

Dactinomycin For Injection USP 500mcg
  • Dactinomycin For Injection USP 500mcg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose500mcg
Packaging SizeSingle Dose Vial
Packaging TypeBox
BrandDACIFLO
CompositionDactinomycin for Injection USP

Indications
  • Uterine cancer
  • Malignant melanoma
  • Testicular cancer
  • Acute lymphocytic leukemia
  • Wilms' tumor
  • Advanced tumors of breast or ovary
  • Rhabdomyosarcoma
  • Paget's disease of bone
  • Ewing's sarcoma Kaposi's sarcoma
  • Sarcoma botryoides
  • Acute organ (kidney or heart) rejection

Dosage
  • Adults 500 mcg (0.5 mg) I.V. daily for a maximum of 5 days. Maximum dose is 15 mcg/kg/day or 400 to 600 mcg/m2/day for 5 days. After bone marrow recovery, course may be repeated.
  • Dose should be based on body surface area in obese or edematous patients.
  • Children 15 mcg/kg (0.015 mg/kg) I.V. daily for a maximum of 5 days. Or, give a total dosage of 2,500 mcg/m2 I.V. over a 1-week period. Maximum dose is 15mcg/kg/day or 400 to 600 mcg/m2/day. After bone marrow recovery, course may be repeated.
  • For isolation-perfusion, use 50 mcg/kg for leg or pelvis; 35 mcg/kg for arm. For second course, wait at least 3 weeks, provided all signs of toxicity have subsided.
Request
Callback
Yes! I am Interested

Daunorubicin Injection 20 mg

Daunorubicin Injection 20 mg
  • Daunorubicin Injection 20 mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose/Strength20mg
Packaging Size1 vial 4 ml
Packaging TypeBox
BrandDORABIN-FH
CompositionDaunorubicin Injection

Indications:
  • Acute myeloblastic Leukemia
  • Neuroblastoma
  • Acute Lymphoblastic Leukemia
  • Rhabdomyosarcoma
  • Acute Non-Lymphatic Leukemia of adults
  • Remission induction in acute Lymphatic Leukemia of children and adults

Dosage:
Starting Doses:
  • The recommended dosage in each individual may vary from 0.5 to 3 mg/ kg.

Acute non-lymphoytic leukemia
  • Patients <60 yrs. of age: 45mg/m2/day.
  • Patients >60 yrs. of age: 30mg/m2/day.

Acute Lymphocytic Leukemia (ALL)
  • Paediatric: 25mg/m2
  • Adult: 45mg/m2

Request
Callback
Yes! I am Interested

Doxorubicin Hydrochloride Liposomal Injection (Pegylated) 20mg/ 50mg

Doxorubicin Hydrochloride Liposomal Injection (Pegylated) 20mg/ 50mg
  • Doxorubicin Hydrochloride Liposomal Injection (Pegylated) 20mg/ 50mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose20mg/ 50mg
Packaging Size1 vial of 10ml, 25ml
Packaging TypeBox
BrandFLODOX-P
CompositionDoxorubicin Hydrochloride Liposomal Injection (Pegylated)

Indications:
  • Doxorubicin hydrochloride liposomal Injection is indicated for the treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel and platinum based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment or within 6 months of completing treatment.
  • Doxorubicin hydrochloride liposomal Injection is indicated as monotherapy for the treatment of metastatic breast cancer, where there is an increased cardiac risk.¿¿¿¿
  • Doxorubicin hydrochloride liposomal Injection is also indicated for the treatment of AIDS related Kaposi's Sarcoma in patients with extensive mucocutaneous or visceral disease that has progressed on prior combination therapy (consisting of two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin or another anthracycline) or in patients who are intolerant to such therapy.

Dose Adjustment:
  • Hepatic Impairment: the dose should be reduced if the bilirubin level is 1.2 mg/dL or greater.
  • Serum bilirubin 1.2 to 3 mg/dL: give 1/2 the normal dose
  • Serum bilirubin greater than 3 mg/dL: give 1/4 the normal dose.
  • Toxicity: adverse reactions, such as hand-foot syndrome, hematologic toxicities, and stomatitis may be managed by dose delay and adjustments.
  • Drug Availability: doxorubicin liposomal injection is supplied as a 20 mg/10mL and 50 mg/25 mL single-use vial.

Dosage:
  • AIDS-related Kaposi's sarcoma
  • Multiple Myeloma
  • Ovarian Cancer
  • IV, intravenous

Dose:
  • 20 mg/m2 IV every 3 weeks until disease progression or unacceptable toxicity.
  • Following bortezomib administration, 30 mg/m2 IV on day 4 every 3 weeks for eight cycles or until disease progression or unacceptable toxicity.
  • (bortezomib: 1.3 mg/m2 bolus on days 1, 4, 8 and 11)
  • 50 mg/m2 every 4 weeks until disease progression or unacceptable toxicity.
Request
Callback
Yes! I am Interested

Flutamide Tablets 250mg

Flutamide Tablets 250mg
  • Flutamide Tablets 250mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging TypeBox
BrandFLUMID-F
Dose250 mg
UseClinical, Hospital, Personal
Packaging Size1x10 tablets

Indications:
  • Flutamide is indicated for the treatment of advanced prostatic carcinoma in which suppression of effects is indicated.
  • Flutamide may be used in combination with an LHRH agonist, both on commencement of treatment or as an adjunctive therapy in patients already receiving an LHRH agonist.
  • Flutamide may also be used in surgically castrated patients.

Dosage:
  • Adults and older people: One tablet three times daily at 8 hour intervals.

Dosage Adjustment:
  • Renal Impairment: Dosing adjustments for renal impairment are not indicated for flutamide.
  • Hepatic Impairment: Discontinue Flutamide if AST ≥ 2 x ULN or bilirubin is > ULN.
Request
Callback
Yes! I am Interested

Hydroxyurea Capsules 500mg

Hydroxyurea Capsules 500mg
  • Hydroxyurea Capsules 500mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging TypeBox
Packaging Size1x10 capsules
Dose500mg
BrandFLOXEA
CompositionHydroxyurea Capsules

Indications:
  • Myeloma.
  • Resistant chronic myelotic leukemia.
  • Recurrent, Metastatic or inoperable carcinoma of the ovary.
  • Primary squamous cell (epidermal) carcinomas of the head and the neck cancer, excluding the lip.
  • Melanoma

Dosage:
  • Adults:- FLOXEA should be started 7 days before concurrent irradiation therapy.
  • Continuous therapy:- FLOXEA 20-30 mg/kg should be given daily in single doses.
  • Intermittent therapy:- FLOXEA 80 mg/kg in single doses should be given every third day.
Request
Callback
Yes! I am Interested

Imatinib Capsules 100mg/400mg

Imatinib Capsules 100mg/400mg
  • Imatinib Capsules 100mg/400mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose100mg/400mg
Packaging Size1x10 capsules
BrandFLOTINIB-100
Pack TypeBox
CompositionImatinib Capsules

Indications:
  • Imatinib is indicated for the treatment of
  • Acute lymphoblastic leukemia
  • Aggressive systemic mastocytosis
  • Chronic myeloid leukemia (CMC)
  • Myelodysplastic disease
  • Gastrointestinal stromal tumor (GIST)

Dosage:
  • 400 mg/day for adult patients in chronic phase, 600 mg/day for adult patients in accelerated phase.
  • The dose of 340 mg/m2 daily is recommended for children with chronic phase.
Request
Callback
Yes! I am Interested

Leucovorin Calcium Injection USP 3mg, 15mg, 50mg

Leucovorin Calcium Injection USP 3mg, 15mg, 50mg
  • Leucovorin Calcium Injection USP 3mg, 15mg, 50mg
Ask For Price
Product Price :Get Latest Price

Product Details:

BrandLEUCO-FH
Dose3mg,15mg,50mg
Packaging Size1 vial of 1/2/5 ml
Pack TypeBox
CompositionLeucovorin Calcium Injection USP

Indications:
  • Leucovorin is used to reduce toxicity following high-dose methotrexate therapy in a process known as “folinic acid rescue”. It can also be used in accidental methotrexate overdose or in cases where excretion of methotrexate from the body is impaired.
  • In advanced bowel cancer, Leucovorin can be used in combination with fluorouracil, as a mediator of cytotoxicity.

Leucovorin has also been shown to be useful in the treatment of megaloblastic anaemias caused by folic acid deficiency. These are known to occur in:
  • Infants
  • Pregnancy
  • Malabsorption syndromes
  • Liver diseases
  • Malnutrition

Dosage:
Duration of calcium folinate rescue primarily depend on the type and dosage of methotrexate therapy, the occurrence of toxicity symptoms, and the individual excretion capacity for methotrexate. As a rule, the first dose of calcium folinate is 15 mg (6-12 mg/m²) to be given 12-24 hours (24 hours at the latest) after the beginning of methotrexate infusion. The same dose is given every 6 hours throughout a period of 72 hours. After several parenteral doses treatment can be switched over to the oral form.
Trimetrexate toxicity:
  • Prevention: Calcium folinate should be administered every day during treatment with trimetrexate and for 72 hours after the last dose of trimetrexate. Calcium folinate can be administered either by the intravenous route at a dose of 20 mg/m² for 5 to 10 minutes every 6 hours for a total daily dose of 80 mg/m², or by oral route with four doses of 20 mg/m2 administered at equal time intervals. Daily doses of calcium folinate should be adjusted depending on the haematological toxicity of trimetrexate.
  • Overdosage (possibly occurring with trimetrexate doses above 90 mg/m2 without concomitant administration of calcium folinate): after stopping trimetrexate, calcium folinate 40 mg/m2 IV every 6 hours for 3 days.

Trimethoprim toxicity:
  • After stopping trimethoprim, 3-10 mg/day calcium folinate until recovery of a normal blood count.
Request
Callback
Yes! I am Interested

Mitomycin For Injection 2mg/10mg/40mg

Mitomycin For Injection 2mg/10mg/40mg
  • Mitomycin For Injection 2mg/10mg/40mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose2mg/10mg/40mg
Packaging Size1 vial
Packaging TypeBox
BrandFLOMIT
CompositionMitomycin for Injection

Indications:
  • Treatment of adenocarcinoma of the stomach or pancreas.
  • Also used in treatment of, bladder, breast, cervical, colorectal, head and neck, and non-small cell lung cancer.

Dosage:
  • As Single Therapy: 12 - 14 mg/m² once a month or every 35 days by intravenous infusion.
  • The crystals are dissolved in 200 mL of a 5% glucose solution which is then administered over a period of 30 minutes, preferably with Vitamin B Compound.
  • As Combination Therapy: 10 mg/m² every 6 - 9 weeks. Higher doses have also been given.
  • Mitomycin-C is usually administered along with other agents (e.g. FOAM –5 FU plus vincristine plus doxorubicin plus mitomycin; SMF –streptozotocin plus mitomycin plus 5 FU; AM – doxorubicin plus mitomycin; FAM –5 FU plus doxorubicin plus mitomycin).
Request
Callback
Yes! I am Interested

Octreotide Acetate Injection 50mcg/ 100mcg/ 200mcg

Octreotide Acetate Injection 50mcg/ 100mcg/ 200mcg
  • Octreotide Acetate Injection 50mcg/ 100mcg/ 200mcg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size1 vial
BrandOCTIDE-F
Packing TypeBox
CompositionOctreotide Acetate Injection
Dose50mcg/100mcg/200mcg

Indications:
  • Symptomatic control and reduction of growth hormone (GH) and IGF-1 plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy.
  • Is also indicated for acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.
  • Relief of symptoms associated with functional gastro-entero-pancreatic (GEP) endocrine tumours, e.g. carcinoid tumours with features of the carcinoid syndrome
  • Itis not an anti-tumour therapy and is not curative in these patients.
  • Prevention of complications following pancreatic surgery.
  • Emergency management to stop bleeding and to protect from re-bleeding owing to gastro-oesophageal varices in patients with cirrhosis. It is to be used in association with specific treatment such as endoscopic sclerotherapy.

Treatment of TSH-secreting pituitary adenomas:
  • When secretion has not normalised after surgery and/or radiotherapy;
  • In patients in whom surgery is inappropriate;
  • In irradiated patients, until radiotherapy is effective.

Dosage:
  • Acromegaly: Initially 0.05 to 0.1 mg by subcutaneous (s.c.) injection every 8 or 12 hours. Dosage adjustment should be based on monthly assessment of GH and IGF-1 levels (target: GH <2.5 ng/mL); IGF-1 within normal range) and clinical symptoms, and on tolerability. In most patients, the optimal daily dose will be 0.3 mg. A maximum dose of 1.5 mg per day should not be exceeded. For patients on a stable dose of Octreotide assessment of GH should be made every 6 months.
  • If no relevant reduction in GH levels and no improvement in clinical symptoms have been achieved within 3 months of starting treatment with Octreotide therapy should be discontinued.
  • Gastro-entero-pancreatic endocrine tumours: Initially 0.05 mg once or twice daily by s.c. injection. Depending on clinical response, effect on levels of tumour-produced hormones (in cases of carcinoid tumours, on the urinary excretion of 5-hydroxyindole acetic acid), and on tolerability, dosage can be gradually increased to 0.1 to 0.2 mg 3 times daily. Under exceptional circumstances, higher doses may be required. Maintenance doses have to be adjusted individually.
  • In carcinoid tumours, if there is no beneficial response within 1 week of treatment with Octreotide at the maximum tolerated dose, therapy should not be continued.
  • Complications following pancreatic surgery: 0.1 mg 3 times daily by s.c. injection for 7 consecutive days, starting on the day of surgery at least 1 hour before laparotomy.
  • Bleeding gastro-oesophageal varices: 25 micrograms/hour for 5 days by continuous intravenous (i.v.) infusion, Octreotide can be used in dilution with physiological saline.
  • In cirrhotic patients with bleeding gastro-oesophageal varices. Octreotide has been well tolerated at continuous i.v. doses of up to 50 micrograms/hour for 5 days.
Request
Callback
Yes! I am Interested

Tamoxifen Tablets 10mg/ 20mg

Tamoxifen Tablets 10mg/ 20mg
  • Tamoxifen Tablets 10mg/ 20mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size1x10 tablets
Packaging TypeBox
Dose10mg/20mg
BrandTAMOX-FH
CompositionTamoxifen Tablets

Indications:
  • As an orally active anti-oestrogen in the treatment of breast cancer. Also used to stimulate ovulation in anovulatory infertility.

Dosage:
  • Breast Cancer: Adults (including the elderly): The dosage range is 20 to 40 mg daily, given either in divided doses twice daily or as a single dose once daily.
  • In early disease, it is currently recommended that treatment is given for not less than 5 years. The optimal duration of tamoxifen therapy remains to be determined.
  • Anovulatory Infertility: In women with regular menstruation but with anovular cycles treatment should commence with 20 mg daily in either one or two doses administered on the second, third, fourth and fifth days of the menstrual cycle. In unsuccessful cases further courses may be given during subsequent menstrual periods, increasing the dosage to 20 mg then 40 mg twice daily.
Request
Callback
Yes! I am Interested

Temozolomide Capsules 20mg/ 100mg/ 250mg

Temozolomide Capsules 20mg/ 100mg/ 250mg
  • Temozolomide Capsules 20mg/ 100mg/ 250mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Dose20mg/100mg/250mg
Packaging Size5 capsules
BrandTEMOLIDE-F
Pack TypeBox
CompositionTemozolomide Capsules

Indications:
  • Temozolomide Capsules is an alkylating drug indicated for the treatment of adult patients with:
  • Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment.
  • Refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.

Dosage:
  • Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temozolomide Capsules for 6 cycles.
  • Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle.
  • Temozolomide Capsules can be administered under both fasting and non-fasting conditions; however, absorption is affected by food and consistency of administration with respect to food is recommended. There are no dietary restrictions with Temozolomide Capsules. To reduce nausea and vomiting, Temozolomide Capsules should be taken on an empty stomach. Bedtime administration may be advised. Antiemetic therapy may be administered prior to and/or following administration of Temozolomide Capsules.
Request
Callback
Yes! I am Interested

Ifosfamide for Injection with Mesna Injection 1g/2g

Ifosfamide for Injection with Mesna Injection 1g/2g
  • Ifosfamide for Injection with Mesna Injection 1g/2g
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging Size1g/2g
Packaging TypeBox
BrandFOSMID-FH
CompositionIfosfamide for Injection with Mesna Injection

Indications:
  • Ifosfamide and mesna is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.

Dosage:
  • injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage weight by weight (w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide.
Request
Callback
Yes! I am Interested
X

Explore more products



Reach Us
Reshma Mishra (CEO)
5/71, Rajeev Gali, Dayal Pur
Delhi -110094,India



Call Us

Share Us

F GT L


Send E-mailSend SMS